Antiandrogen Flutamide Protects Male Mice From Androgen-Dependent Toxicity in Three Models of Spinal Bulbar Muscular Atrophy

• Published in: Endocrinology (Philadelphia) Vol. 155; no. 7; pp. 2624 - 2634
• Main Authors: Renier, Kayla J., Troxell-Smith, Sandra M., Johansen, Jamie A., Katsuno, Masahisa, Adachi, Hiroaki, Sobue, Gen, Chua, Jason P., Sun Kim, Hong, Lieberman, Andrew P., Breedlove, S. Marc, Jordan, Cynthia L.
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 01.07.2014; Endocrine Society
• Subjects: Androgen Antagonists - pharmacology; Androgen receptors; Androgens; Androgens - metabolism; Animal models; Animals; Antagonists; Atrophy; Blotting, Western; Bulbo-Spinal Atrophy, X-Linked - drug therapy; Bulbo-Spinal Atrophy, X-Linked - genetics; Bulbo-Spinal Atrophy, X-Linked - metabolism; Disease Models, Animal; Flutamide; Flutamide - pharmacology; Life span; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscles; Neurodegenerative diseases; Neuroendocrinology; Orchiectomy; Peptides - genetics; Polyglutamine diseases; Receptors, Androgen - genetics; Receptors, Androgen - metabolism; Spinal and bulbar muscular atrophy; Survival Analysis; Time Factors; Toxicity; Transgenic mice; Treatment Outcome; Trinucleotide repeat diseases; Trinucleotide Repeat Expansion - genetics

Spinal and bulbar muscular atrophy (SBMA) is a late-onset, progressive neurodegenerative disease linked to a polyglutamine (polyQ) expansion in the androgen receptor (AR). Men affected by SBMA show marked muscle weakness and atrophy, typically emerging midlife. Given the androgen-dependent nature of...